DiFMDA (original) (raw)
Difluoromethylenedioxyamphetamine (DiFMDA) is a substituted derivative of 3,4-methylenedioxyamphetamine (MDA), which was developed by Daniel Trachsel and coworkers, along with the corresponding fluorinated derivatives of MDMA, MDEA, BDB and MBDB, with the aim of finding a non-neurotoxic drug able to be used as a less harmful substitute for entactogenic drugs such as MDMA. Since a major route of the normal metabolism of these compounds is scission of the methylenedioxy ring, producing neurotoxic metabolites such as alpha-methyldopamine, it was hoped that the difluoromethylenedioxy bioisostere would show increased metabolic stability and less toxicity.
| Property | Value |
|---|---|
| dbo:abstract | Difluoromethylenedioxyamphetamine (DiFMDA) is a substituted derivative of 3,4-methylenedioxyamphetamine (MDA), which was developed by Daniel Trachsel and coworkers, along with the corresponding fluorinated derivatives of MDMA, MDEA, BDB and MBDB, with the aim of finding a non-neurotoxic drug able to be used as a less harmful substitute for entactogenic drugs such as MDMA. Since a major route of the normal metabolism of these compounds is scission of the methylenedioxy ring, producing neurotoxic metabolites such as alpha-methyldopamine, it was hoped that the difluoromethylenedioxy bioisostere would show increased metabolic stability and less toxicity. These compounds have not yet been tested in animals to verify whether they show similar pharmacological activity to the non-fluorinated parent compounds, although in vitro binding studies show DFMDA to have a SERT affinity in between that of MDA and MDMA. It is also now generally accepted that MDMA neurotoxicity results from a variety of different causes and is not solely due to accumulation of alpha-methyldopamine, making it unclear how much less neurotoxic DFMDA and related drugs would be in practice. (en) |
| dbo:casNumber | 910393-51-0 |
| dbo:fdaUniiCode | 8Q2ANL037S |
| dbo:pubchem | 57467735 |
| dbo:thumbnail | wiki-commons:Special:FilePath/DFMDA.svg?width=300 |
| dbo:wikiPageID | 31366022 (xsd:integer) |
| dbo:wikiPageLength | 4573 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1109808114 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Methylenedioxy dbc:Designer_drugs dbc:Entactogens_and_empathogens dbc:Organofluorides dbc:Serotonin_releasing_agents dbr:Alpha-methyldopamine dbr:MDMA dbc:Substituted_amphetamines dbr:Bioisostere dbr:3,4-methylenedioxyamphetamine dbr:Entactogen dbr:Serotonin_transporter |
| dbp:atcPrefix | none (en) |
| dbp:c | 10 (xsd:integer) |
| dbp:casNumber | 910393 (xsd:integer) |
| dbp:chemspiderid | 26495356 (xsd:integer) |
| dbp:f | 2 (xsd:integer) |
| dbp:h | 11 (xsd:integer) |
| dbp:iupacName | 1 (xsd:integer) |
| dbp:legalCa | Schedule I (en) |
| dbp:legalDe | NpSG (en) |
| dbp:legalUk | Class A (en) |
| dbp:n | 1 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 57467735 (xsd:integer) |
| dbp:smiles | CCN (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | BHDXKBALNFHXDV-UHFFFAOYSA-N (en) |
| dbp:unii | 8 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 451607745 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Entactogens dbt:Monoamine_releasing_agents dbt:Phenethylamines dbt:Reflist dbt:Cascite dbt:Fdacite |
| dcterms:subject | dbc:Designer_drugs dbc:Entactogens_and_empathogens dbc:Organofluorides dbc:Serotonin_releasing_agents dbc:Substituted_amphetamines |
| gold:hypernym | dbr:Derivative |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAmphetamines yago:Agent114778436 yago:Amphetamine102704153 yago:CausalAgent100007347 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Stimulant104320126 yago:Substance100020090 |
| rdfs:comment | Difluoromethylenedioxyamphetamine (DiFMDA) is a substituted derivative of 3,4-methylenedioxyamphetamine (MDA), which was developed by Daniel Trachsel and coworkers, along with the corresponding fluorinated derivatives of MDMA, MDEA, BDB and MBDB, with the aim of finding a non-neurotoxic drug able to be used as a less harmful substitute for entactogenic drugs such as MDMA. Since a major route of the normal metabolism of these compounds is scission of the methylenedioxy ring, producing neurotoxic metabolites such as alpha-methyldopamine, it was hoped that the difluoromethylenedioxy bioisostere would show increased metabolic stability and less toxicity. (en) |
| rdfs:label | DiFMDA (en) |
| owl:sameAs | freebase:DiFMDA yago-res:DiFMDA wikidata:DiFMDA dbpedia-sh:DiFMDA dbpedia-sr:DiFMDA https://global.dbpedia.org/id/4j9cU |
| prov:wasDerivedFrom | wikipedia-en:DiFMDA?oldid=1109808114&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/DFMDA.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:DiFMDA |
| is dbo:wikiPageRedirects of | dbr:DFMDA dbr:2,2-Difluoro-1,3-benzodioxolylpropanamine dbr:2,2-difluoro-1,3-benzodioxolylpropanamine dbr:Difluoromethylenedioxyamphetamine |
| is dbo:wikiPageWikiLink of | dbr:List_of_designer_drugs dbr:List_of_psychedelic_drugs dbr:3,4-Ethylidenedioxyamphetamine dbr:5-APDI dbr:DFMDA dbr:Substituted_methylenedioxyphenethylamine dbr:2,2-Difluoro-1,3-benzodioxolylpropanamine dbr:2,2-difluoro-1,3-benzodioxolylpropanamine dbr:Difluoromethylenedioxyamphetamine |
| is foaf:primaryTopic of | wikipedia-en:DiFMDA |
